Skip to content
European Centre for Disease Prevention and Control (ECDC) - Logo
The European Union Drugs Agency (EUDA) - Logo

References

  • (Aebi MF, Cocco E. (2024). Aebi, M. F. & Cocco, E. (2024)). Prisons and Prisoners in Europe 2023: Key Findings of the SPACE I report. Series UNILCRIM 2024/1. Council of Europe and University of Lausanne.

  • (Bennett, H, 2015). Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. PLoS One. 2015 May 4;10(5):e0125846. doi: 10.1371/journal.pone.0125846.

  • (Dolan K, 2016). Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016 Sep 10;388(10049):1089-1102. doi: 10.1016/S0140-6736(16)30466-4.

  • (EASL, 2017). European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021.

  • (EASL, 2025). European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025 May 8:S0168-8278(25)00174-6. doi: 10.1016/j.jhep.2025.03.018.

  • (EASL, 2020). European Association for the Study of the Liver. Clinical Practice Guidelines EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020 Nov;73(5):1170-1218. doi:10.1016/j.jhep.2020.08.018.

  • (ECDC, 2018). European Centre for Disease Prevention and Control. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-hep-testing-guidance_0.pdf

  • (ECDC, 2024). European Centre for Disease Prevention and Control. Monitoring of the responses to the hepatitis B and C epidemics in EU/EEA countries, 2023. Stockholm: ECDC; 2024. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Monitoring-responses-hepatitis-B-C-epidemics.pdf

  • (ECDC/EMCDDA, 2018). European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Public health guidance on prevention and control of blood-borne viruses in prison settings. Stockholm: ECDC and EMCDDA; 2018. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-on-BBV-in-prisons.pdf

  • (ECDC/EMCDDA, 2018b). European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Public health guidance on active case finding of communicable diseases in prison settings. Stockholm and Lisbon: ECDC and EMCDDA; 2018. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Active-case-finding-communicable-diseases-in-prisons.pdf

  • (ECDC/EMCDDA, 2023). European Centre for Disease Prevention and Control (ECDC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention and control of infectious diseases among people who inject drugs: 2023 update. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-prevention-control-PWID-6-November.pdf

  • (European Commission, 2024). European Commission. Council Recommendation of 21 June 2024 on vaccine-preventable cancers. C/2024/4259. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:C_202404259

  • (EMCDDA, 2022). European Monitoring Centre for Drugs and Drug Addiction (2022), Prison and drugs in Europe: current and future challenges, Publications Office of the European Union, Luxembourg. Available at: https://www.euda.europa.eu/publications/insights/prison-and-drugs-in-europe_en

  • (EMCDDA, 2023). European Monitoring Centre for Drugs and Drug Addiction (2023), Migrants and drugs: health and social responses. Available at https://www.emcdda.europa.eu/publications/mini-guides/migrants-and-drugs-health-and-social-responses

  • (EMCDDA, 2024). European Monitoring Centre for Drugs and Drug Addiction (2024), European Drug Report 2024: Trends and Developments. Available at https://www.emcdda.europa.eu/publications/european-drug-report/2024_en

  • (He T, 2016). He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med. 2016 Jan 19;164(2):84-92. doi: 10.7326/M15-0617.

  • (INHSU Prisons, 2024). International Network on Hepatitis in Substance Users (INHSU) Prisons. Global Guidelines for Viral Hepatitis Service Delivery in Prisons. August 2024. Available at: https://www.inhsu.org/wp-content/uploads/2024/09/Global-Guidelines_FINAL.pdf

  • (Pan American Health Organization, 2017). Pan American Health Organization. Framework for elimination of mother-to-child transmission of HIV, Syphilis, Hepatitis B, and Chagas. Published online 2017. http://iris.paho.org/xmlui/handle/123456789/34306

  • (Shih, STF, 2023). Shih STF, Stone J, Martin NK, Hajarizadeh B, Cunningham EB, Kwon JA, et al. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination. Open Forum Infect Dis. 2023 Dec 18;11(2):ofad637. doi: 10.1093/ofid/ofad637.

  • (Stasi C, 2020). Stasi C, Silvestri C, Voller F. Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res. 2020 Jan;9(1):1-7. doi: 10.7774/cevr.2020.9.1.1.

  • (Shenge JA, Osiowy C, 2021). Shenge, JA., and Osiowy C. Rapid diagnostics for hepatitis B and C viruses in low-and middle-income countries. Frontiers in Virology. 2021: 742722.

  • (Silbernagl M, 2018). Silbernagl M, Slamanig R, Fischer G, Brandt L. Hepatitis C infection and psychiatric burden in two imprisoned cohorts: Young offenders and opioid-maintained prisoners. Health Policy. 2018 Dec;122(12):1392-1402. doi: 10.1016/j.healthpol.2018.10.005.

  • (Trickey A, 2019). Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444. doi: 10.1016/S2468-1253(19)30085-8.

  • (UNODC, 2018). United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Available at: https://www.unodc.org/wdr2018/

  • (Van de Baan FC, 2022). Van de Baan FC, Montanari L, Royuela L, Lemmens PH. Prevalence of illicit drug use before imprisonment in Europe: Results from a comprehensive literature review. Drugs: Education, Prevention and Policy, 29 (1) (2022), pp. 1-12, 10.1080/09687637.2021.1879022.

  • (Van den Bergh, BJ, 2011). Van den Bergh BJ, Gatherer A, Fraser A, Moller L. Imprisonment and women’s health: concerns about gender sensitivity, human rights and public health. Bull World Health Organ. 2011 Sep 1;89(9):689-94. doi: 10.2471/BLT.10.082842.

  • (Vickerman P, 2011). Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2011 Jan 15;113(2-3):83-5; discussion 86-7. doi: 10.1016/j.drugalcdep.2010.08.001.

  • (WHO, 2018). World Health Organisation (WHO). HBV screening and accelerated vaccination in prison. 2018. Available at: https://www.who.int/europe/teams/alcohol-illicit-drugs-prison-health/hbv-screening-and-accelerated-vaccination-in-prison-(2018)

  • (WHO, 2022). World Health Organisation Regional Office for Europe (WHO). Good practices in managing infectious diseases in prison settings: a snapshot of responses to COVID-19 implemented around the globe between May and September 2020. Copenhagen: WHO Regional Office for Europe; 2022. Available at: https://www.who.int/europe/publications/i/item/WHO-EURO-2022-5206-44970-64017

  • (WHO, 2024). World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. Licence: CC BYNC-SA 3.0 IGO. Available at: https://www.who.int/publications/i/item/9789240090903